NICE describes gout as a lifelong condition that benefits from long-term management. For people using urate-lowering therapy, treatment is usually continued after the serum urate target is reached and is typically lifelong.
NICE describes gout as a lifelong condition that benefits from long-term management. For people using urate-lowering therapy, treatment is usually continued after the serum urate target is reached and is typically lifelong.
NICE describes gout as a lifelong condition that benefits from long-term management. For people using urate-lowering therapy, treatment is usually continued after the serum urate target is reached and is typically lifelong.
Read the primary guidance/source →
General educational information, not individual medical advice. Evidence reviewed September 2026.
General educational information, not individual medical advice. Do not start, stop or change prescribed treatment based on this page.